STERIS plc $STE Shares Sold by Waratah Capital Advisors Ltd.

Waratah Capital Advisors Ltd. lessened its stake in STERIS plc (NYSE:STE) by 13.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 5,856 shares of the medical equipment provider’s stock after selling 874 shares during the period. Waratah Capital Advisors Ltd.’s holdings in STERIS were worth $1,407,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Spurstone Advisory Services LLC acquired a new position in shares of STERIS in the second quarter valued at approximately $29,000. Geneos Wealth Management Inc. increased its stake in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 104 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in STERIS during the first quarter worth approximately $37,000. Costello Asset Management INC purchased a new stake in shares of STERIS during the 1st quarter worth approximately $45,000. Finally, Atticus Wealth Management LLC purchased a new stake in shares of STERIS during the 2nd quarter worth approximately $68,000. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Stock Performance

NYSE:STE opened at $258.75 on Friday. The company has a market cap of $25.40 billion, a P/E ratio of 39.62 and a beta of 1.02. The firm’s 50 day moving average is $245.98 and its two-hundred day moving average is $240.35. STERIS plc has a fifty-two week low of $200.98 and a fifty-two week high of $268.30. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period last year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Analysts expect that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s payout ratio is currently 36.21%.

Wall Street Analyst Weigh In

Several brokerages recently commented on STE. Morgan Stanley lifted their price target on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. KeyCorp raised their price objective on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research report on Tuesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Finally, Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $273.50.

Insider Activity at STERIS

In other STERIS news, VP John Adam Zangerle sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the transaction, the vice president owned 33,669 shares in the company, valued at $8,926,998.66. This represents a 30.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel A. Carestio sold 159 shares of the business’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $241.82, for a total transaction of $38,449.38. Following the completion of the transaction, the chief executive officer owned 51,096 shares in the company, valued at $12,356,034.72. This represents a 0.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 18,363 shares of company stock worth $4,814,114. Company insiders own 1.07% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.